

Sunil Iyengar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9509548/publications.pdf>

Version: 2024-02-01

45
papers

1,216
citations

758635

12
h-index

454577

30
g-index

45
all docs

45
docs citations

45
times ranked

2754
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of cardiovascular complications of bruton tyrosine kinase inhibitors. British Journal of Haematology, 2022, 196, 70-78.	1.2	14
2	Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment. Leukemia and Lymphoma, 2022, 63, 562-572.	0.6	4
3	Treatment Response Assessment Maps (TRAMs), a new tool for CNS lymphoma. EJHaem, 2022, 3, 247-248.	0.4	1
4	Cost and clinical benefit of imaging surveillance after treatment for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). European Journal of Surgical Oncology, 2022, 48, 748-751.	0.5	0
5	A very rare complication of subdural haematoma: fibrin-associated diffuse large B-cell lymphoma. British Journal of Haematology, 2021, 192, 947-947.	1.2	2
6	18 F-choline radiotracer positron emission tomography as a new means to monitor central nervous system lymphoma. British Journal of Haematology, 2021, 193, 1026-1026.	1.2	4
7	Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia, 2021, 35, 1864-1872.	3.3	28
8	Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): Quantifying the direct economic costs of post-treatment radiological surveillance.. Journal of Clinical Oncology, 2021, 39, e19574-e19574.	0.8	0
9	Pulmonary manifestations of grade III lymphomatoid granulomatosis complicated by haemophagocytic lymphohistiocytosis: Rare disorders. EJHaem, 2021, 2, 669-670.	0.4	0
10	Are treatment response assessment maps (TRAMs) and 18 F-choline positron emission tomography the future of central nervous system lymphoma imaging?. British Journal of Haematology, 2021, 195, e116-e119.	1.2	2
11	A case of neurolymphomatosis: A rare complication of diffuse large B-cell lymphoma. EJHaem, 2021, 2, 305-306.	0.4	0
12	Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?. Bone Marrow Transplantation, 2021, , .	1.3	0
13	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature Cancer, 2021, 2, 1305-1320.	5.7	123
14	Real World Escalated Beacopdac Delivers Similar Outcomes to Escalated Beacopp and Superior Outcomes to Response-Adapted (RATHL) ABVD, While Potentially Reducing Toxicity Compared with Escalated Beacopp. Blood, 2021, 138, 877-877.	0.6	3
15	Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Cost Evaluation Study of Management and Surveillance, and Review of the Recent USA and UK Guidelines. Blood, 2021, 138, 4014-4014.	0.6	0
16	Avenue - Avelumab in the Frontline Treatment of Advanced Classic Hodgkin Lymphoma - a Window Study. Blood, 2021, 138, 2470-2470.	0.6	0
17	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematology, the, 2020, 7, e112-e121.	2.2	119
18	Early interval and serial positron emission tomography-computed tomography (PET-CT) after an indeterminate response defined by a PET scored 4 on the Deauville scale in lymphoma. British Journal of Haematology, 2020, 190, e357-e362.	1.2	0

#	ARTICLE	IF	CITATIONS
19	CLL-151: Richter Syndrome: Clinical Characteristic, Treatment, and Outcome in a Single Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S223.	0.2	0
20	Haematological cancers and the risk of severe COVID-19: Exploration and critical evaluation of the evidence to date. <i>British Journal of Haematology</i> , 2020, 190, 336-345.	1.2	27
21	Focal splenic lesions in indolent B-NHL: association with high grade transformation and safe percutaneous biopsy. <i>British Journal of Haematology</i> , 2020, 189, e157-e160.	1.2	2
22	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	3.3	198
23	LyRIC indeterminate response and Immune-mediated pseudoprogression of diffuse large B-cell lymphoma following polatuzumab-based salvage therapy. <i>British Journal of Haematology</i> , 2020, 189, e248-e251.	1.2	3
24	Breast Implant-associated Anaplastic Large Cell Lymphoma: Review and Multiparametric Imaging Paradigms. <i>Radiographics</i> , 2020, 40, 609-628.	1.4	46
25	Dabrafenib Is a Safe and Effective Therapy in Relapsed/Refractory Classical Hairy Cell Leukemia. <i>Blood</i> , 2020, 136, 7-8.	0.6	3
26	Targeted Next Generation Sequencing Improves Diagnosis in Unclassifiable Leukemic Indolent B-Cell Non-Hodgkin Lymphoma and Identifies a Subset with Recurrent MYD88 Mutations in a Prospective Multicentre Study. <i>Blood</i> , 2020, 136, 12-13.	0.6	0
27	The Value of Follow-up Following Complete Remission with Frontline Chemotherapy for DLBCL. <i>Blood</i> , 2020, 136, 31-32.	0.6	0
28	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	0.6	2
29	Hairy Cell Leukaemia: From Hairy Beginnings to a BRAF New World. <i>British Journal of Haematology</i> , 2020, 191, 527-534.	1.2	0
30	Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. <i>Haematologica</i> , 2019, 104, e68-e71.	1.7	97
31	No Improvement in Survival for T-PLL Patients over the Last Two Decades. <i>Blood</i> , 2019, 134, 1552-1552.	0.6	3
32	Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study. <i>Blood</i> , 2019, 134, 5268-5268.	0.6	1
33	Implementing a Specialist Integrated Haematological Malignancy Imaging Reporting Paradigm to Lymphoma Radiology Assessment Can Significantly Improve the Quality of Data for Patient Management and Clinical Research. <i>Blood</i> , 2019, 134, 5835-5835.	0.6	1
34	Procarbazine-Free Escalated Beacopdac in Frontline Therapy of Advanced Hodgkin Lymphoma Reduces Red Cell Transfusion Requirements and May Shorten Time to Menstrual Period Recovery Compared to Escalated Beacopp and Appears to be As Efficacious. <i>Blood</i> , 2019, 134, 1564-1564.	0.6	2
35	Acalabrutinib in Patients (pts) with Waldenström Macroglobulinemia (WM). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S285-S286.	0.2	1
36	Guideline for the treatment of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2018, 182, 344-359.	1.2	29

#	ARTICLE	IF	CITATIONS
37	Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).. Journal of Clinical Oncology, 2018, 36, 7501-7501.	0.8	11
38	Durable Remissions Achieved with R-CHOP Chemotherapy without Radiotherapy in Patients with Primary Mediastinal B-Cell Lymphoma - the Royal Marsden Experience. Blood, 2018, 132, 4240-4240.	0.6	0
39	Evolution of lymphoma staging and response evaluation: current limitations and future directions. Nature Reviews Clinical Oncology, 2017, 14, 631-645.	12.5	26
40	Characteristics of human primary mantle cell lymphoma engraftment in NSG mice. British Journal of Haematology, 2016, 173, 165-169.	1.2	3
41	Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study. Lancet Haematology, the, 2016, 3, e196-e204.	2.2	344
42	Extramedullary haematopoiesis in chronic lymphocytic leukaemia. British Journal of Haematology, 2015, 171, 442-442.	1.2	1
43	P110 α -mediated constitutive PI3K signaling limits the efficacy of p110 δ -selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood, 2013, 121, 2274-2284.	0.6	116
44	Abstract 4489: The activity of novel, potent, selective PI3K/mTOR pathway inhibitors in B-cell malignancies. , 2010, , .		0
45	[18F]Fluoromethylcholine PET/CT for CNS lymphoma assessment: a new tool. F1000Research, 0, 10, 1137.	0.8	0